The GLP-1 landscape has evolved dramatically over the past several years. In 2025, patients have more options than ever, and the evidence base for these therapies is stronger and more nuanced than at any prior point. But "more options" also means more confusion about which peptide is right for whom.
This guide cuts through the noise with a clear-eyed, evidence-based summary of where the field stands in 2025.
The Current Evidence Hierarchy
Tirzepatide: The Current Efficacy Leader
Tirzepatide, the dual GIP/GLP-1 receptor agonist, currently holds the top position on average weight loss efficacy. The SURMOUNT-1 trial (72 weeks) showed:
- Average weight loss of 20.9 percent at 15 mg (highest dose)
- 37 percent of participants lost 25 percent or more of their body weight at the highest dose
- Consistent superiority over semaglutide in the SURPASS-2 head-to-head trial
For patients who are appropriate candidates and whose primary goal is maximum fat loss, tirzepatide is currently the evidence-based first choice.
Semaglutide: Proven, Well-Understood, Widely Used
Semaglutide has the longest clinical track record of any GLP-1 receptor agonist, with the most data on long-term cardiovascular outcomes (SELECT trial) and the widest physician familiarity. It remains an excellent first-line choice, particularly for:
- Patients new to GLP-1 therapy
- Those with established cardiovascular disease (strongest outcome data)
- Patients where the higher efficacy of tirzepatide is not the primary priority
Average weight loss: 14 to 17 percent at 2.4 mg weekly over 68 weeks in the STEP trials.
Retatrutide: The Emerging Triple Agonist
Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data published in the New England Journal of Medicine showed average weight loss of 17.5 percent at 12 mg over 24 weeks - a trajectory suggesting 30 percent plus at full duration. Phase 3 trials are ongoing as of 2025, and it is not yet commercially available.
It represents the most significant near-term development in the field and is worth monitoring for patients who plateau on current options.
CagriSema: Semaglutide + Amylin Agonist Combination
CagriSema combines semaglutide with cagrilintide (an amylin analogue) and showed average weight loss of 22.7 percent in Phase 3 trials, comparable to tirzepatide with a distinct mechanism. This combination is in late-stage development as of 2025.
How to Choose in Practice
The "best" GLP-1 in 2025 is not a fixed answer. It depends on:
- Your metabolic profile: Insulin resistance patterns and GIP receptor sensitivity influence which pathway produces the best response for you
- Your weight loss goal: If maximum fat loss is the priority and you are an appropriate candidate, tirzepatide's efficacy edge is meaningful
- Your cardiovascular risk: Semaglutide's extensive cardiovascular outcome data may be the deciding factor for patients with established heart disease
- Prior treatment history: Non-responders or partial responders to semaglutide are strong candidates for tirzepatide
- Tolerability: Individual GI sensitivity varies; some patients tolerate one peptide's specific side effect profile better than another's
Beyond GLP-1: The Supporting Stack
The best weight loss outcome in 2025 is often achieved not with a single peptide in isolation but with a thoughtfully designed protocol. Longegra's approach considers whether supporting peptides, including growth hormone secretagogues like Ipamorelin for muscle preservation or BPC-157 for GI support, would improve your overall outcome.
The Longegra Approach
Longegra stays current with the evolving evidence base and adjusts physician recommendations as new data emerge. Our intake process includes a full biomarker panel and clinical consultation specifically to determine which currently available peptide is most appropriate for each patient's unique profile.
Frequently Asked Questions (FAQs)
If you have been on semaglutide for 12 months or more and have not reached your goal weight, a switch to tirzepatide is a reasonable clinical discussion. It should be physician-supervised with careful dose mapping to avoid an abrupt transition.
